Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma

Objective Immune checkpoint inhibitors (ICI) have become a major treatment in advanced non small cell lung cancer (NSCLC). However, some patients do not benefit from ICI, especially those harboring an ALK rearrangement. Here, we report a case of prolonged complete tumor response to immunotherapy in an ALK-rearranged NSCLC patient. Materials and Methods We verify ALK expression and rearrangement on formalin-fixed paraffin-embedded tumor samples...